Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Valero

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancerV Valero, A U Buzdar, R L Theriault, et al.
Breast Cancer Research and Treatment|February 19, 2011
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancersT R Lester, K K Hunt, K M Nayeemuddin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2009
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancerU De Giorgi, V Valero, E Rohren, et al.
Cancer Investigation|July 19, 2001
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalationN K Ibrahim, V Valero, Z Rahman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2008
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsM Cristofanilli, P Morandi, S Krishnamurthy, et al.
Clinical & Experimental Metastasis|February 2, 2013
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutationsS Bayraktar, A M Gutierrez-Barrera, H Lin, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2001
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapyT A Buchholz, B S Hill, S L Tucker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 4, 2011
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyA Giordano, M Giuliano, M De Laurentiis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experienceR A Brito, V Valero, A U Buzdar, et al.
Cancer|December 18, 2001
Paclitaxel in the multimodality treatment for inflammatory breast carcinomaM Cristofanilli, A U Buzdar, N Sneige, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancerV Valero, A U Buzdar, R L Theriault, et al.
Breast Cancer Research and Treatment|February 19, 2011
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancersT R Lester, K K Hunt, K M Nayeemuddin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2009
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancerU De Giorgi, V Valero, E Rohren, et al.
Cancer Investigation|July 19, 2001
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalationN K Ibrahim, V Valero, Z Rahman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2008
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsM Cristofanilli, P Morandi, S Krishnamurthy, et al.
Clinical & Experimental Metastasis|February 2, 2013
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutationsS Bayraktar, A M Gutierrez-Barrera, H Lin, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2001
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapyT A Buchholz, B S Hill, S L Tucker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 4, 2011
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyA Giordano, M Giuliano, M De Laurentiis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experienceR A Brito, V Valero, A U Buzdar, et al.
Cancer|December 18, 2001
Paclitaxel in the multimodality treatment for inflammatory breast carcinomaM Cristofanilli, A U Buzdar, N Sneige, et al.
Pageof 12